Seer, Inc. (NASDAQ:SEER) Sees Large Decrease in Short Interest

Seer, Inc. (NASDAQ:SEER) was the target of a significant drop in short interest during the month of December. As of December 31st, there was short interest totaling 279,535 shares, a drop of 82.1% from the December 15th total of 1,563,815 shares. Approximately 0.6% of the shares of the company are short sold. Based on an average trading volume of 212,773 shares, the short-interest ratio is currently 1.3 days. Based on an average trading volume of 212,773 shares, the short-interest ratio is currently 1.3 days. Approximately 0.6% of the shares of the company are short sold.

Insider Transactions at Seer

In related news, CEO Omid Farokhzad sold 33,838 shares of the business’s stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $1.97, for a total transaction of $66,660.86. Following the transaction, the chief executive officer owned 1,238,230 shares of the company’s stock, valued at approximately $2,439,313.10. The trade was a 2.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 11.28% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. lifted its holdings in shares of Seer by 51.6% during the first quarter. Goldman Sachs Group Inc. now owns 170,897 shares of the company’s stock valued at $289,000 after acquiring an additional 58,173 shares during the period. Jane Street Group LLC grew its holdings in shares of Seer by 33.3% in the 1st quarter. Jane Street Group LLC now owns 254,174 shares of the company’s stock worth $430,000 after purchasing an additional 63,432 shares during the last quarter. Susquehanna International Group LLP increased its position in shares of Seer by 22.8% during the 3rd quarter. Susquehanna International Group LLP now owns 123,447 shares of the company’s stock worth $268,000 after purchasing an additional 22,918 shares in the last quarter. Squarepoint Ops LLC lifted its holdings in Seer by 57.0% during the 3rd quarter. Squarepoint Ops LLC now owns 91,906 shares of the company’s stock valued at $199,000 after purchasing an additional 33,349 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in Seer during the 2nd quarter valued at about $172,000. 75.20% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

SEER has been the topic of several research analyst reports. Wall Street Zen upgraded shares of Seer to a “hold” rating in a research report on Saturday, December 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Seer in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Seer Stock Performance

Seer stock remained flat at $1.95 on Monday. 137,614 shares of the company’s stock traded hands, compared to its average volume of 166,543. Seer has a 12-month low of $1.62 and a 12-month high of $2.44. The stock has a market capitalization of $108.79 million, a price-to-earnings ratio of -1.43 and a beta of 1.60. The firm has a 50 day simple moving average of $1.92 and a two-hundred day simple moving average of $2.07.

Seer (NASDAQ:SEER) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.01. The company had revenue of $4.12 million during the quarter, compared to the consensus estimate of $4.00 million. Seer had a negative net margin of 484.51% and a negative return on equity of 25.88%. On average, analysts predict that Seer will post -1.42 EPS for the current fiscal year.

About Seer

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.